<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): March 25, 2009</B>

<P style="font-size: 24pt" align="center"><B>Safeguard Scientifics,
Inc.<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Pennsylvania</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>1-5620</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>23-1609753</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>435 Devon Park Drive,
Building 800, Wayne, PA<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>19087</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>610-293-0600</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>Not
applicable<BR>
</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>



<DIV style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left"><B>ITEM
1.01</B>.&nbsp;&nbsp;&nbsp;&nbsp; <U><B>Entry into a Material Definitive
Agreement.</B></U>

<P style="font-size: 10pt" align="left">On March&nbsp;25, 2009, Clarient, Inc.
(&#8220;Clarient&#8221;), a majority-owned subsidiary of the Company, entered
into a Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;), with
Oak Investment Partners XII, Limited Partnership, a Delaware limited
partnership (&#8220;Oak&#8221;), pursuant to which Clarient agreed to sell and
issue to Oak up to an aggregate of 6,578,948 shares of the Company&#8217;s
Series&nbsp;A Convertible Preferred Stock, $0.01 par value (the
&#8220;Preferred Shares&#8221;) in two or more tranches (the &#8220;Private
Placement&#8221;) for aggregate consideration of up to $50.0&nbsp;million. The
initial closing of the Private Placement occurred on March&nbsp;26, 2009, at
which time Clarient issued and sold an aggregate of 3,833,201 Preferred Shares
for aggregate consideration of approximately $29.1&nbsp;million (&#8220;Initial
Closing&#8221;). The second closing under the Purchase Agreement for an
additional 1,429,957 Preferred Shares for consideration of approximately $10.9
million will occur no later than the second business day following the
satisfaction or waiver of the conditions precedent to the second closing set
forth in the Purchase Agreement, including the filing of an Information
Statement with the Securities and Exchange Commission describing the
stockholder action being taken to approve the Private Placement and the
distribution of such Information Statement to all Clarient stockholders in
accordance with Delaware law and the rules of the Securities and Exchange
Commission and the Nasdaq Marketplace. Pursuant to the Stockholders Agreement
(as defined below), Safeguard Delaware, Inc. (&#8220;SDI&#8221;) and Safeguard
Scientifics (Delaware), Inc. (&#8220;SSDI&#8221;), wholly owned subsidiaries of
Safeguard Scientifics, Inc. (&#8220;Safeguard&#8221;), have approved the
issuance of the Preferred Shares via written consent. The remaining Preferred
Shares will be issued and sold pursuant to the Purchase Agreement only upon the
further mutual agreement of Clarient and Oak and the satisfaction of all
conditions precedent to such closings contained in the Purchase Agreement.
Neither party is obligated to consummate the sale and purchase of such
remaining Preferred Shares. A portion of the net proceeds of the Initial
Closing were used to repay $14&nbsp;million of amounts outstanding under the
Safeguard Loan Agreement (as defined below) and to pay off all amounts
outstanding under the Comerica Loan Agreement (as defined below).

<P style="font-size: 10pt" align="left">In connection with the Private
Placement:

<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD nowrap align="left" width="3%">&#8226;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>SDI, SSDI and Safeguard entered into a Stockholders Agreement with Oak
(&#8220;Stockholders Agreement&#8221;) pursuant to which they agreed, among
other matters, to vote the securities they own in favor of the Private
Placement.</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD nowrap align="left" width="3%">&#8226;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>Clarient and SDI amended certain provisions of the Securities Purchase
Agreement dated as of June&nbsp;13, 2002, between Clarient and SDI. The
amendment provides that Safeguard is entitled to nominate up to three directors
to the Clarient Board of Directors for so long as Safeguard and/or its
transferee(s) hold at least 25% of the voting power of all outstanding
securities of Clarient.</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD nowrap align="left" width="3%">&#8226;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>Clarient and SDI amended certain provisions of the Second Amended and
Restated Senior Subordinated Revolving Credit Agreement, dated
February&nbsp;27, 2009, by and between Clarient and SDI (the &#8220;Safeguard
Loan Agreement&#8221;). The material amendments to the Safeguard Loan Agreement
are as follows: (i)&nbsp;the maximum aggregate principal amount which may be
borrowed under the terms of the Safeguard Loan Agreement, inclusive of those
amounts currently outstanding, is reduced from $30.0&nbsp;million to
$10.0&nbsp;million; and (ii)&nbsp;the repayment in full of Clarient&#8217;s
debt under, and the termination of, the Amended and Restated Loan Agreement,
dated as of February&nbsp;28, 2008 (as modified and amended from time to time),
by and between Comerica Bank and Clarient (the &#8220;Comerica Loan
Agreement&#8221;) at the Initial Closing is permitted.</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD nowrap align="left" width="3%">&#8226;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>The Safeguard Guaranty (as defined below) and the Reimbursement and
Indemnity Agreement (as defined below) were terminated, and the Safeguard cash
collateral securing such guaranty was released.</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">The information set forth above is
qualified in its entirety by reference to the Amendment to the Securities
Purchase Agreement dated March&nbsp;26, 2009, by and between Clarient and SDI
and its affiliates (Exhibit&nbsp;10.1), the First Amendment and Consent to the
Second Amended and Restated Senior Subordinated Revolving Credit Agreement
dated March&nbsp;26, 2009, by and between Clarient and SDI (Exhibit&nbsp;10.2),
and the Stockholders Agreement dated March&nbsp;26, 2009, among SDI, SSDI,
Safeguard and Oak (Exhibit&nbsp;10.3), which documents are incorporated herein
by reference. A copy of Safeguard&#146;s press release is attached hereto
as Exhibit&nbsp;99.1 and is incorporated herein by reference.

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left"><B>ITEM 1.02. </B><U><B>Termination of
a Material Definitive Agreement</B></U>

<P style="font-size: 10pt" align="left">The disclosure set forth above under
Item&nbsp;1.01 is hereby incorporated by reference into this Item&nbsp;1.02.

<P style="font-size: 10pt" align="left">In connection with the termination of
the Comerica Loan Agreement, that certain Third Amended and Restated
Unconditional Guaranty dated January&nbsp;17, 2007, by Safeguard in favor of
Comerica Bank (as amended, the &#8220;Safeguard Guaranty&#8221;) was
terminated. As a result of the termination of the Safeguard Guaranty, that
certain Amended and Restated Reimbursement and Indemnity Agreement dated
January&nbsp;17, 2007, as amended, between Clarient and Safeguard
(&#8220;Reimbursement and Indemnity Agreement&#8221;) automatically terminated.

<P style="font-size: 10pt" align="left"><B>ITEM 9.01. </B><U><B>Financial
Statements and Exhibits</B></U>

<P style="font-size: 10pt" align="left">(d)&nbsp;Exhibits

<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="4%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">10.1</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>Amendment to Securities Purchase Agreement dated March&nbsp;26, 2009, by
and between Clarient, Inc. and Safeguard Delaware, Inc. and its affiliates
(incorporated by reference to Exhibit&nbsp;10.4 of the Current Report on Form
8-K filed on March&nbsp;27, 2009 by Clarient, Inc. (SEC File
No.&nbsp;000-22677))</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="4%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">10.2</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>First Amendment and Consent to Second Amended and Restated Senior
Subordinated Revolving Credit Agreement dated March&nbsp;26, 2009 by and
between Safeguard Delaware, Inc. and Clarient, Inc. (incorporated by reference
to Exhibit&nbsp;10.5 of the Current Report on Form 8-K filed on March&nbsp;27,
2009 by Clarient, Inc. (SEC File No.&nbsp;000-22677))</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="4%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">10.3</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>Stockholders Agreement dated March&nbsp;26, 2009 by and among Safeguard
Delaware, Inc., Safeguard Scientifics, Inc., Safeguard Scientifics (Delaware),
Inc. and Oak Investment Partners XII, Limited Partnership (incorporated by
reference to Exhibit&nbsp;10.6 of the Current Report on Form 8-K filed on March
27, 2009 by Clarient, Inc. (SEC File No.&nbsp;000-22677))</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="4%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">99.1</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>Press release dated March&nbsp;26, 2009</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">SIGNATURES

<P style="font-size: 10pt" align="left">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
  <TD width="48%">&nbsp;</TD>
  <TD width="4%">&nbsp;</TD>
  <TD width="48%">&nbsp;</TD>
</TR>

 <TR valign="top">
  <TD>&nbsp;</TD>
  <TD colspan="2" align="left">Safeguard Scientifics, Inc.</TD>
</TR>


<TR><TD>&nbsp;</TD></TR>

<TR>
  <TD align="left">Dated: March&nbsp;27, 2009</TD>
  <TD align="left"> By:</TD>
  <TD align="left" style="border-bottom: 1px solid #000000">BRIAN J. SISKO</TD>
</TR>

 <TR valign="top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align="left">Brian J. Sisko<BR>
Senior Vice President and General Counsel</TD>
</TR>
</TABLE>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c83165e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 15641}]
{"company-data": {"conformed-name": "SAFEGUARD SCIENTIFICS INC", "cik": "0000086115", "assigned-sic": "7389", "irs-number": "231609753", "state-of-incorporation": "PA", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-05620", "film-number": "09709574"}, "business-address": {"street1": "435 DEVON PARK DR", "street2": "BLDG 800", "city": "WAYNE", "state": "PA", "zip": "19087", "phone": "6102930600"}, "mail-address": {"street1": "435 DEVON PARK DR", "street2": "BLDG 800", "city": "WAYNE", "state": "PA", "zip": "19087"}, "former-company": [{"former-conformed-name": "SAFEGUARD INDUSTRIES INC", "date-changed": "19810525"}, {"former-conformed-name": "SAFEGUARD CORP", "date-changed": "19690521"}]}
Form 8-K
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): March 25, 2009
Safeguard Scientifics,
Inc.
(Exact name of registrant as
specified in its charter)
Pennsylvania
1-5620
23-1609753
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
435 Devon Park Drive,
Building 800, Wayne, PA
19087
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number,
including area code:
610-293-0600
Not
applicable
(Former name or former address if changed since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM
1.01
.
Entry into a Material Definitive
Agreement.
On March 25, 2009, Clarient, Inc.
("Clarient"), a majority-owned subsidiary of the Company, entered
into a Stock Purchase Agreement (the "Purchase Agreement"), with
Oak Investment Partners XII, Limited Partnership, a Delaware limited
partnership ("Oak"), pursuant to which Clarient agreed to sell and
issue to Oak up to an aggregate of 6,578,948 shares of the Company's
Series A Convertible Preferred Stock, $0.01 par value (the
"Preferred Shares") in two or more tranches (the "Private
Placement") for aggregate consideration of up to $50.0 million. The
initial closing of the Private Placement occurred on March 26, 2009, at
which time Clarient issued and sold an aggregate of 3,833,201 Preferred Shares
for aggregate consideration of approximately $29.1 million ("Initial
Closing"). The second closing under the Purchase Agreement for an
additional 1,429,957 Preferred Shares for consideration of approximately $10.9
million will occur no later than the second business day following the
satisfaction or waiver of the conditions precedent to the second closing set
forth in the Purchase Agreement, including the filing of an Information
Statement with the Securities and Exchange Commission describing the
stockholder action being taken to approve the Private Placement and the
distribution of such Information Statement to all Clarient stockholders in
accordance with Delaware law and the rules of the Securities and Exchange
Commission and the Nasdaq Marketplace. Pursuant to the Stockholders Agreement
(as defined below), Safeguard Delaware, Inc. ("SDI") and Safeguard
Scientifics (Delaware), Inc. ("SSDI"), wholly owned subsidiaries of
Safeguard Scientifics, Inc. ("Safeguard"), have approved the
issuance of the Preferred Shares via written consent. The remaining Preferred
Shares will be issued and sold pursuant to the Purchase Agreement only upon the
further mutual agreement of Clarient and Oak and the satisfaction of all
conditions precedent to such closings contained in the Purchase Agreement.
Neither party is obligated to consummate the sale and purchase of such
remaining Preferred Shares. A portion of the net proceeds of the Initial
Closing were used to repay $14 million of amounts outstanding under the
Safeguard Loan Agreement (as defined below) and to pay off all amounts
outstanding under the Comerica Loan Agreement (as defined below).
In connection with the Private
Placement:
•
SDI, SSDI and Safeguard entered into a Stockholders Agreement with Oak
("Stockholders Agreement") pursuant to which they agreed, among
other matters, to vote the securities they own in favor of the Private
Placement.
•
Clarient and SDI amended certain provisions of the Securities Purchase
Agreement dated as of June 13, 2002, between Clarient and SDI. The
amendment provides that Safeguard is entitled to nominate up to three directors
to the Clarient Board of Directors for so long as Safeguard and/or its
transferee(s) hold at least 25% of the voting power of all outstanding
securities of Clarient.
•
Clarient and SDI amended certain provisions of the Second Amended and
Restated Senior Subordinated Revolving Credit Agreement, dated
February 27, 2009, by and between Clarient and SDI (the "Safeguard
Loan Agreement"). The material amendments to the Safeguard Loan Agreement
are as follows: (i) the maximum aggregate principal amount which may be
borrowed under the terms of the Safeguard Loan Agreement, inclusive of those
amounts currently outstanding, is reduced from $30.0 million to
$10.0 million; and (ii) the repayment in full of Clarient's
debt under, and the termination of, the Amended and Restated Loan Agreement,
dated as of February 28, 2008 (as modified and amended from time to time),
by and between Comerica Bank and Clarient (the "Comerica Loan
Agreement") at the Initial Closing is permitted.
•
The Safeguard Guaranty (as defined below) and the Reimbursement and
Indemnity Agreement (as defined below) were terminated, and the Safeguard cash
collateral securing such guaranty was released.
The information set forth above is
qualified in its entirety by reference to the Amendment to the Securities
Purchase Agreement dated March 26, 2009, by and between Clarient and SDI
and its affiliates (Exhibit 10.1), the First Amendment and Consent to the
Second Amended and Restated Senior Subordinated Revolving Credit Agreement
dated March 26, 2009, by and between Clarient and SDI (Exhibit 10.2),
and the Stockholders Agreement dated March 26, 2009, among SDI, SSDI,
Safeguard and Oak (Exhibit 10.3), which documents are incorporated herein
by reference. A copy of Safeguard's press release is attached hereto
as Exhibit 99.1 and is incorporated herein by reference.
ITEM 1.02.
Termination of
a Material Definitive Agreement
The disclosure set forth above under
Item 1.01 is hereby incorporated by reference into this Item 1.02.
In connection with the termination of
the Comerica Loan Agreement, that certain Third Amended and Restated
Unconditional Guaranty dated January 17, 2007, by Safeguard in favor of
Comerica Bank (as amended, the "Safeguard Guaranty") was
terminated. As a result of the termination of the Safeguard Guaranty, that
certain Amended and Restated Reimbursement and Indemnity Agreement dated
January 17, 2007, as amended, between Clarient and Safeguard
("Reimbursement and Indemnity Agreement") automatically terminated.
ITEM 9.01.
Financial
Statements and Exhibits
(d) Exhibits
10.1
Amendment to Securities Purchase Agreement dated March 26, 2009, by
and between Clarient, Inc. and Safeguard Delaware, Inc. and its affiliates
(incorporated by reference to Exhibit 10.4 of the Current Report on Form
8-K filed on March 27, 2009 by Clarient, Inc. (SEC File
No. 000-22677))
10.2
First Amendment and Consent to Second Amended and Restated Senior
Subordinated Revolving Credit Agreement dated March 26, 2009 by and
between Safeguard Delaware, Inc. and Clarient, Inc. (incorporated by reference
to Exhibit 10.5 of the Current Report on Form 8-K filed on March 27,
2009 by Clarient, Inc. (SEC File No. 000-22677))
10.3
Stockholders Agreement dated March 26, 2009 by and among Safeguard
Delaware, Inc., Safeguard Scientifics, Inc., Safeguard Scientifics (Delaware),
Inc. and Oak Investment Partners XII, Limited Partnership (incorporated by
reference to Exhibit 10.6 of the Current Report on Form 8-K filed on March
27, 2009 by Clarient, Inc. (SEC File No. 000-22677))
99.1
Press release dated March 26, 2009
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
Safeguard Scientifics, Inc.
Dated: March 27, 2009
By:
BRIAN J. SISKO
Brian J. Sisko
Senior Vice President and General Counsel